COVID-19 危重症患者合并血栓栓塞时的抗磷脂抗体：是病因还是伴随现象？
Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?
机构信息
Emergency Department and Critical Care Area, Anesthesia and Intensive Care Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy.
Department of Anesthesia and Intensive Care, Orthopedic Anesthesia, University-Hospital Careggi, Largo Palagi, 1, 50139, Florence, Italy.
出版信息
J Thromb Thrombolysis. 2021 Aug;52(2):542-552. doi: 10.1007/s11239-021-02470-y. Epub 2021 May 10.
Abstract
Coronavirus 2019 disease (COVID-19) is associated with coagulation dysfunction that predisposes patients to an increased risk for both arterial (ATE) and venous thromboembolism (VTE) and consequent poor prognosis; in particular, the incidence of ATE and VTE in critically ill COVID-19 patients can reach 5% and 31%, respectively. The mechanism of thrombosis in COVID-19 patients is complex and still not completely clear. Recent literature suggests a link between the presence of antiphospholipid antibodies (aPLs) and thromboembolism in COVID-19 patients. However, it remains uncertain whether aPLs are an epiphenomenon or are involved in the pathogenesis of the disease.
摘要
新型冠状病毒病（COVID-19）与凝血功能障碍相关，使患者发生动脉血栓栓塞（ATE）和静脉血栓栓塞（VTE）的风险增加，并导致预后不良；特别是，危重症 COVID-19 患者的 ATE 和 VTE 发生率分别可达 5%和 31%。COVID-19 患者的血栓形成机制复杂，目前尚不完全清楚。最近的文献提示 COVID-19 患者存在抗磷脂抗体（aPLs）与血栓栓塞之间存在关联。但是，目前仍不确定 aPLs 是一种伴随现象还是参与了疾病的发病机制。
相似文献
1
Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?COVID-19 危重症患者合并血栓栓塞时的抗磷脂抗体：是病因还是伴随现象？
J Thromb Thrombolysis. 2021 Aug;52(2):542-552. doi: 10.1007/s11239-021-02470-y. Epub 2021 May 10.
2
Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study.COVID-19 患者入住重症监护病房时抗磷脂抗体的流行率和临床意义：一项前瞻性观察研究。
Rheumatol Int. 2021 Jul;41(7):1243-1252. doi: 10.1007/s00296-021-04875-7. Epub 2021 May 5.
3
Antiphospholipid Antibodies in Critically Ill Patients With COVID-19.COVID-19 重症患者的抗磷脂抗体。
Arthritis Rheumatol. 2020 Dec;72(12):1998-2004. doi: 10.1002/art.41425. Epub 2020 Oct 7.
4
Antiphospholipid antibodies in patients with COVID-19: A relevant observation?COVID-19 患者中的抗磷脂抗体：一个相关观察？
J Thromb Haemost. 2020 Sep;18(9):2191-2201. doi: 10.1111/jth.14994. Epub 2020 Jul 23.
5
[Antiphospholipid antibodies as risk factor for venous thromboembolism].[抗磷脂抗体作为静脉血栓栓塞的危险因素]
Pol Arch Med Wewn. 2002 Nov;108(5):1065-70.
6
Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome.抗磷脂抗体和抗磷脂综合征的危险因素。
Semin Thromb Hemost. 2024 Sep;50(6):817-828. doi: 10.1055/s-0043-1776910. Epub 2024 Jan 16.
7
Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients.危重症 COVID-19 阳性和阴性患者中的抗心磷脂抗体和其他抗磷脂抗体。
Ann Rheum Dis. 2021 Sep;80(9):1236-1240. doi: 10.1136/annrheumdis-2021-220206. Epub 2021 Apr 26.
8
Antiphospholipid antibodies in patients with coronavirus disease 2019 infection hospitalized in conventional unit.COVID-19 感染住院患者的常规治疗单元中的抗磷脂抗体。
Blood Coagul Fibrinolysis. 2021 Mar 1;32(2):73-79. doi: 10.1097/MBC.0000000000000963.
9
Solid cancer, antiphospholipid antibodies, and venous thromboembolism.实体瘤、抗磷脂抗体与静脉血栓栓塞症。
Autoimmun Rev. 2011 Feb;10(4):222-7. doi: 10.1016/j.autrev.2010.10.006. Epub 2010 Oct 16.
10
High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability?危重症 COVID-19 患者抗磷脂抗体的高频率：与高凝状态有关联？
J Intern Med. 2021 Mar;289(3):422-424. doi: 10.1111/joim.13126. Epub 2020 Jul 13.
引用本文的文献
1
Antiphospholipid antibodies in patients with COVID-19: a systematic review and meta-analysis.新型冠状病毒肺炎患者的抗磷脂抗体：一项系统评价与荟萃分析
J Thromb Thrombolysis. 2025 Jul 5. doi: 10.1007/s11239-025-03116-z.
2
Cardiovascular Symposium on Perspectives in Long COVID.长新冠视角下的心血管研讨会
Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251319963. doi: 10.1177/10760296251319963.
3
Thromboembolic Disease and COVID-19: Experience of a University and Emergency Hospital During the Pandemic.血栓栓塞性疾病与新型冠状病毒肺炎：一所大学及急诊医院在疫情期间的经验
Cureus. 2024 Sep 6;16(9):e68767. doi: 10.7759/cureus.68767. eCollection 2024 Sep.
4
Thrombosis and Hyperinflammation in COVID-19 Acute Phase Are Related to Anti-Phosphatidylserine and Anti-Phosphatidylinositol Antibody Positivity.新冠病毒疾病急性期的血栓形成和过度炎症与抗磷脂酰丝氨酸和抗磷脂酰肌醇抗体阳性有关。
Biomedicines. 2023 Aug 18;11(8):2301. doi: 10.3390/biomedicines11082301.
5
Thromboembolism in the Complications of Long COVID-19.新冠长期并发症中的血栓栓塞
Cardiol Cardiovasc Med. 2023;7(2):123-128. doi: 10.26502/fccm.92920317. Epub 2023 Apr 20.
6
Changes in the Level of Antiphospholipid Antibodies (Anticardiolipin and Anti-β2-Glycoprotein-I) and Thromboembolic Indices in COVID-19 Patients during 3 Weeks.COVID-19患者在3周内抗磷脂抗体（抗心磷脂抗体和抗β2-糖蛋白-I）水平及血栓栓塞指标的变化
Int J Prev Med. 2023 Mar 21;14:38. doi: 10.4103/ijpvm.ijpvm_377_21. eCollection 2023.
7
Biological mechanisms underpinning the development of long COVID.长期新冠发展背后的生物学机制。
iScience. 2023 Jun 16;26(6):106935. doi: 10.1016/j.isci.2023.106935. Epub 2023 May 18.
8
The risk of venous thromboembolism and blood hyperlactatemia is associated with increased mortality among critically ill patients with Covid-19.静脉血栓栓塞和血液高乳酸血症的风险与 COVID-19 重症患者的死亡率增加有关。
Clin Respir J. 2023 Jun;17(6):580-588. doi: 10.1111/crj.13628. Epub 2023 May 5.
9
Factors Related to Severity, Hospitalization, and Mortality of COVID-19 Infection among Patients with Autoimmune Diseases.自身免疫性疾病患者中与新型冠状病毒肺炎感染严重程度、住院率及死亡率相关的因素
Trop Med Infect Dis. 2023 Apr 18;8(4):227. doi: 10.3390/tropicalmed8040227.
10
Hospitalized patients with positive antiphospholipid antibodies who have low complement levels are at increased risk for death-a retrospective cohort study.伴有低补体水平的抗磷脂抗体阳性住院患者死亡风险增加：一项回顾性队列研究。
Lupus. 2023 Apr;32(5):668-674. doi: 10.1177/09612033231164091. Epub 2023 Mar 23.
本文引用的文献
1
SARS-CoV-2 infection and thrombotic complications: a narrative review.SARS-CoV-2 感染与血栓并发症：叙述性综述。
J Thromb Thrombolysis. 2021 Jul;52(1):111-123. doi: 10.1007/s11239-020-02374-3. Epub 2021 Jan 15.
2
Antiphospholipid Autoantibodies and Thrombosis in Patients With COVID-19: Comment on the Article by Bertin et al.新冠病毒疾病患者的抗磷脂自身抗体与血栓形成：对Bertin等人文章的评论
Arthritis Rheumatol. 2021 May;73(5):897-899. doi: 10.1002/art.41634. Epub 2021 Mar 16.
3
Thromboembolism, Hypercoagulopathy, and Antiphospholipid Antibodies in Critically Ill Coronavirus Disease 2019 Patients: A Before and After Study of Enhanced Anticoagulation.2019年冠状病毒病重症患者的血栓栓塞、高凝状态及抗磷脂抗体：强化抗凝治疗的前后对照研究
Crit Care Explor. 2020 Dec 17;2(12):e0308. doi: 10.1097/CCE.0000000000000308. eCollection 2020 Dec.
4
Cell-Type-Specific Immune Dysregulation in Severely Ill COVID-19 Patients.COVID-19 重症患者的细胞类型特异性免疫失调。
Cell Rep. 2021 Jan 5;34(1):108590. doi: 10.1016/j.celrep.2020.108590. Epub 2020 Dec 16.
5
Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis.2019冠状病毒病的血栓栓塞风险很高，且与更高的死亡风险相关：一项系统评价和荟萃分析。
EClinicalMedicine. 2020 Dec;29:100639. doi: 10.1016/j.eclinm.2020.100639. Epub 2020 Nov 20.
6
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome.COVID-19 中的抗磷脂抗体与抗磷脂综合征中可检测到的抗体不同。
Front Immunol. 2020 Oct 15;11:584241. doi: 10.3389/fimmu.2020.584241. eCollection 2020.
7
Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19.COVID-19 住院患者血清中的促血栓形成自身抗体。
Sci Transl Med. 2020 Nov 18;12(570). doi: 10.1126/scitranslmed.abd3876. Epub 2020 Nov 2.
8
Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies.重症2019冠状病毒病（COVID-19）与血清免疫球蛋白（Ig）A及抗磷脂IgA抗体升高有关。
Clin Infect Dis. 2021 Nov 2;73(9):e2869-e2874. doi: 10.1093/cid/ciaa1496.
9
Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action.危重症 COVID-19 患者接受高于标准低分子肝素剂量和阿司匹林治疗时的静脉血栓栓塞和出血：行动呼吁。
Thromb Res. 2020 Dec;196:313-317. doi: 10.1016/j.thromres.2020.09.013. Epub 2020 Sep 13.
10
Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis.COVID-19 患者的静脉血栓栓塞症：系统评价和荟萃分析。
Thromb Res. 2020 Dec;196:67-74. doi: 10.1016/j.thromres.2020.08.020. Epub 2020 Aug 12.
Zotero 插件